Emergent BioSolutions (NYSE:EBS) Shares Gap Up After Analyst Upgrade

Emergent BioSolutions Inc. (NYSE:EBS)’s stock price gapped up before the market opened on Thursday after Benchmark raised their price target on the stock from $8.00 to $12.00. The stock had previously closed at $9.20, but opened at $11.43. Benchmark currently has a buy rating on the stock. Emergent BioSolutions shares last traded at $12.32, with a volume of 1,642,442 shares trading hands.

Separately, Rodman & Renshaw reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Institutional Investors Weigh In On Emergent BioSolutions

Institutional investors and hedge funds have recently modified their holdings of the company. CWM LLC raised its position in Emergent BioSolutions by 32,706.7% during the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 4,906 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Emergent BioSolutions during the second quarter worth $41,000. Verus Capital Partners LLC acquired a new position in Emergent BioSolutions during the second quarter valued at $68,000. Tidal Investments LLC purchased a new stake in Emergent BioSolutions in the first quarter valued at $34,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Emergent BioSolutions during the 2nd quarter worth about $93,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Price Performance

The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.54 and a current ratio of 1.06. The firm has a market cap of $582.01 million, a PE ratio of -0.98 and a beta of 1.57. The stock has a 50 day simple moving average of $8.36 and a two-hundred day simple moving average of $7.67.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.35). The company had revenue of $254.70 million during the quarter, compared to analyst estimates of $199.47 million. Emergent BioSolutions had a negative net margin of 53.26% and a negative return on equity of 34.38%. During the same period in the previous year, the firm posted ($1.06) earnings per share. Sell-side analysts expect that Emergent BioSolutions Inc. will post -1.3 earnings per share for the current year.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.